TABLE 2.

Logistic Regression Model for Predictors of Gain of VL Suppression Among Previously Unsuppressed CALHIV After Shifting to DTG

Characteristic (N)	OR (95% CI)
Pre-DTG ART regimen
NNRTI-based (n = 5700)*	1 (REF)
PI-based (n = 1457)	1.53 (1.16–2.03)
Country/Site
Botswana (n = 903)*	1 (REF)
Eswatini (n = 1022)	1.33 (0.80–2.21)
Lesotho (n = 1042)	1.09 (0.63–1.89)
Malawi (n = 1272)	0.78 (0.45–1.35)
Tanzania (n = 922)	5.45 (3.41–8.70)
Uganda (n = 2399)	1.49 (0.92–2.43)
Age category
0–4.99 years (n = 5)	Indet.†
5–9.99 years (n = 432)	0.69 (0.47–1.00)
10–14.99 years (n = 815)*	1 (REF)
15–19.99 years (n = 866)	1.31 (1.03–1.65)
Sex
Female (n = 3814)	0.94 (0.75–1.17)
Male (n = 3746)*	1

^*Reference Category within variable.

^†Indeterminant due to small sample size and/or outcome event rate not allowing for enough power to report an OR.

ART indicates antiretroviral therapy; CALHIV, children and adolescents living with HIV; CI, Confidence Interval; DTG, dolutegravir; N/A, not applicable; NNRTI, nonnucleoside reverse transcriptase inhibitor; OR, odds ratio; PI, protease inhibitor; VL, viral load.